menu
    • menu

    Find Quinapril manufacturers, exporters & distributors on PharmaCompass

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    13

    API Suppliers

    API Suppliers

    11

    USDMF

    US DMFs Filed

    4

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    5

    EU WC

    EU WC

    0

    KDMF

    KDMF

    5

    NDC API

    NDC API

    0

    VMF

    NDC API

    6

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 730

    MARKET PLACE

    6

    API

    1

    FDF

    5INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    201

    FDF Dossiers

    FDF Dossiers

    77

    FDA Orange Book

    FDA (Orange Book)

    90

    Europe

    Europe

    4

    Canada

    Canada

    4

    Australia

    Australia

    26

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    2DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    3

    EDQM

    2

    USP

    0

    JP

    3

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    32

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    16

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    12,404,399

    Annual Reports

    NA

    Finished Drug Prices

    Listed Dossiers

    254 RELATED EXCIPIENT COMPANIES

    430EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 82586-55-8, Accupril, Quinapril hcl, Accuprin, Korec, Acequin
    Molecular Formula
    C25H31ClN2O5
    Molecular Weight
    475.0  g/mol
    InChI Key
    IBBLRJGOOANPTQ-JKVLGAQCSA-N
    FDA UNII
    33067B3N2M
    Quinapril
    A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.
    1 2D Structure

    Quinapril

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid;hydrochloride
    2.1.2 InChI
    InChI=1S/C25H30N2O5.ClH/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30;/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30);1H/t17-,21-,22-;/m0./s1
    2.1.3 InChI Key
    IBBLRJGOOANPTQ-JKVLGAQCSA-N
    2.1.4 Canonical SMILES
    CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CC3=CC=CC=C3CC2C(=O)O.Cl
    2.1.5 Isomeric SMILES
    CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O.Cl
    2.2 Other Identifiers
    2.2.1 UNII
    33067B3N2M
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic Acid

    2. Accupril

    3. Ci 906

    4. Ci-906

    5. Pd 109,452 2

    6. Pd 109452 2

    7. Pd 109452-2

    8. Pd 1094522

    9. Pd-109,452-2

    10. Quinapril

    2.3.2 Depositor-Supplied Synonyms

    1. 82586-55-8

    2. Accupril

    3. Quinapril Hcl

    4. Accuprin

    5. Korec

    6. Acequin

    7. Quinazil

    8. Hemokvin

    9. Lidaltrin

    10. Acuitel

    11. Ectren

    12. Conan

    13. Quinapril (hydrochloride)

    14. Accupro

    15. Ci-906

    16. Quinapril.hcl

    17. Ci906

    18. Ci 906

    19. Quinaprilhydrochloride

    20. Quinapril Hydrochloride

    21. Nsc-758222

    22. Chebi:8714

    23. Quinapril Hydrochloride (accupril)

    24. 33067b3n2m

    25. (3s)-2-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1h-isoquinoline-3-carboxylic Acid;hydrochloride

    26. (s)-2-(((s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-l-alanyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid Hydrochloride

    27. (s)-2-((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic Acid, 1-ethyl Ester, Monohydrochloride

    28. Accupron

    29. Acuprel

    30. Continucor

    31. Koretic

    32. Asig

    33. Dsstox_cid_1221

    34. Dsstox_rid_76019

    35. Dsstox_gsid_21221

    36. (s)-2-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid Hydrochloride

    37. Cas-82586-55-8

    38. Quinapril Hydrochloride [usan]

    39. Hsdb 7046

    40. Pd 109452-2

    41. Unii-33067b3n2m

    42. Quinapril N-oxide

    43. Ncgc00094997-01

    44. Accupril (tn)

    45. Quinapril Hydrochloride [usan:usp]

    46. Mfcd00889215

    47. Quinapril Hydrochloride;

    48. Schembl41404

    49. Mls001076683

    50. Quinapril Hydrochloride ,(s)

    51. Spectrum1503076

    52. Quinapril Hydrochloride- Bio-x

    53. Quinapril For System Suitability

    54. Chembl1201011

    55. Dtxsid3021221

    56. Quinapril For Peak Identification

    57. Hms1922c15

    58. Pharmakon1600-01503076

    59. Tetrahydroisoquinoline-3-carboxylic

    60. Hy-b0477

    61. 2-ylamino)propanoyl)-1,2,3,4-

    62. Quinapril Hydrochloride [mi]

    63. Tox21_111381

    64. Tox21_200390

    65. Ccg-39543

    66. Nsc758222

    67. Quinapril Hydrochloride (jp17/usp)

    68. Quinapril Hydrochloride [jan]

    69. S2581

    70. Quinapril Hydrochloride [hsdb]

    71. Akos015888532

    72. Pd-109452-2

    73. Tox21_111381_1

    74. Ac-1655

    75. Nc00722

    76. Nsc 758222

    77. Quinapril Hydrochloride [mart.]

    78. Quinapril Hydrochloride [vandf]

    79. Quinapril Hydrochloride [usp-rs]

    80. Quinapril Hydrochloride [who-dd]

    81. Ncgc00167962-06

    82. Ncgc00257944-01

    83. (3s)-2-(n-{(1s)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-l-alanyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid Hydrochloride

    84. (3s)-2-[(2s)-2-{[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid Hydrochloride

    85. 3-isoquinolinecarboxylic Acid, 1,2,3,4-tetrahydro-2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, Monohydrochloride, (3s-(2(r*(r*)),3r*))-

    86. 3-isoquinolinecarboxylic Acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-, Monohydrochloride, (3s-(2(r*(r*)),3r*))

    87. As-14026

    88. Bq164301

    89. Smr000499582

    90. Pd-109522

    91. Pd109452-2

    92. Quinapril Hydrochloride [orange Book]

    93. Sw199393-2

    94. Quinapril Hydrochloride [ep Monograph]

    95. Quinapril Hydrochloride [usp Impurity]

    96. C07340

    97. D00459

    98. F20594

    99. Quinapril Hydrochloride [usp Monograph]

    100. Quinapril Hydrochloride, >=98% (hplc), Solid

    101. 586q558

    102. A840381

    103. Accuretic Component Quinapril Hydrochloride

    104. Quinaretic Component Quinapril Hydrochloride

    105. Sr-01000765404

    106. Sr-01000765404-2

    107. Q27108138

    108. Quinapril Hydrochloride Component Of Accuretic

    109. Quinapril Hydrochloride Component Of Quinaretic

    110. (s)-2-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-

    111. Quinapril Hydrochloride, European Pharmacopoeia (ep) Reference Standard

    112. Quinapril Hydrochloride, United States Pharmacopeia (usp) Reference Standard

    113. Quinapril For Peak Identification, European Pharmacopoeia (ep) Reference Standard

    114. Quinapril For System Suitability, European Pharmacopoeia (ep) Reference Standard

    115. Quinapril Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

    116. (3s)-2-{(2s)-2-[(1s)-1-ethoxycarbonyl-3-phenylpropylamino]propanoyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid Hydrochloride

    117. (3s)-2-{n-[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-l-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid Hydrochloride

    118. 2-(2-((1-ethoxycarbonyl-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic Acid Monohydrochloride(3s-(2(r*(r*)),3r*)

    2.4 Create Date
    2004-09-16
    3 Chemical and Physical Properties
    Molecular Weight 475.0 g/mol
    Molecular Formula C25H31ClN2O5
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count10
    Exact Mass474.1921498 g/mol
    Monoisotopic Mass474.1921498 g/mol
    Topological Polar Surface Area95.9 Ų
    Heavy Atom Count33
    Formal Charge0
    Complexity648
    Isotope Atom Count0
    Defined Atom Stereocenter Count3
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 6  
    Drug NameAccupril
    PubMed HealthQuinapril (By mouth)
    Drug ClassesAntihypertensive, Cardiovascular Agent, Renal Protective Agent
    Drug LabelACCUPRIL (quinapril hydrochloride) is the hydrochloride salt of quinapril, the ethyl ester of a non-sulfhydryl, angiotensin-converting enzyme (ACE) inhibitor, quinaprilat.Quinapril hydrochloride is chemically described as [3S-[2[R*(R*)], 3R*]]-2-[2...
    Active IngredientQuinapril hydrochloride
    Dosage FormTablet
    RouteOral
    Strengtheq 40mg base; eq 5mg base; eq 20mg base; eq 10mg base
    Market StatusPrescription
    CompanyPfizer Pharms

    2 of 6  
    Drug NameAccuretic
    PubMed HealthQuinapril/Hydrochlorothiazide (By mouth)
    Drug ClassesACE Inhibitor/Thiazide Combination, Antihypertensive, Cardiovascular Agent
    Active IngredientHydrochlorothiazide; quinapril hydrochloride
    Dosage FormTablet
    RouteOral
    Strength25mg; eq 20mg base; eq 10mg base; 12.5mg
    Market StatusPrescription
    CompanyPfizer Pharms

    3 of 6  
    Drug NameQuinapril hydrochloride
    Drug LabelQuinapril hydrochloride is the hydrochloride salt of quinapril, the ethyl ester of a non-sulfhydryl, angiotensin-converting enzyme (ACE) inhibitor, quinaprilat.Quinapril hydrochloride is chemically described as [3S-[2[R*(R*)], 3R*]]-2-[2-[[1-(ethox...
    Active IngredientQuinapril hydrochloride
    Dosage FormTablet
    RouteOral
    Strengtheq 5mg base; eq 20mg base; eq 40mg base; eq 10mg base
    Market StatusPrescription
    CompanyRanbaxy; Actavis Labs Fl; Teva; Aurobindo Pharma; Sun Pharm Inds; Lupin; Invagen Pharms; Mylan

    4 of 6  
    Drug NameAccupril
    PubMed HealthQuinapril (By mouth)
    Drug ClassesAntihypertensive, Cardiovascular Agent, Renal Protective Agent
    Drug LabelACCUPRIL (quinapril hydrochloride) is the hydrochloride salt of quinapril, the ethyl ester of a non-sulfhydryl, angiotensin-converting enzyme (ACE) inhibitor, quinaprilat.Quinapril hydrochloride is chemically described as [3S-[2[R*(R*)], 3R*]]-2-[2...
    Active IngredientQuinapril hydrochloride
    Dosage FormTablet
    RouteOral
    Strengtheq 40mg base; eq 5mg base; eq 20mg base; eq 10mg base
    Market StatusPrescription
    CompanyPfizer Pharms

    5 of 6  
    Drug NameAccuretic
    PubMed HealthQuinapril/Hydrochlorothiazide (By mouth)
    Drug ClassesACE Inhibitor/Thiazide Combination, Antihypertensive, Cardiovascular Agent
    Active IngredientHydrochlorothiazide; quinapril hydrochloride
    Dosage FormTablet
    RouteOral
    Strength25mg; eq 20mg base; eq 10mg base; 12.5mg
    Market StatusPrescription
    CompanyPfizer Pharms

    6 of 6  
    Drug NameQuinapril hydrochloride
    Drug LabelQuinapril hydrochloride is the hydrochloride salt of quinapril, the ethyl ester of a non-sulfhydryl, angiotensin-converting enzyme (ACE) inhibitor, quinaprilat.Quinapril hydrochloride is chemically described as [3S-[2[R*(R*)], 3R*]]-2-[2-[[1-(ethox...
    Active IngredientQuinapril hydrochloride
    Dosage FormTablet
    RouteOral
    Strengtheq 5mg base; eq 20mg base; eq 40mg base; eq 10mg base
    Market StatusPrescription
    CompanyRanbaxy; Actavis Labs Fl; Teva; Aurobindo Pharma; Sun Pharm Inds; Lupin; Invagen Pharms; Mylan

    4.2 Therapeutic Uses

    ... /Quinapril/ has proven to be very useful for the treatment of hypertension ... . /Salt not specified/

    Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 893

    The angiotensin converting enzyme (ACE) inhibitors appear to confer a special advantage in the treatment of patients with diabetes, slowing the development of diabetic glomerulopathy. They also have been shown to be effective in slowing the progression of other forms of chronic renal disease, such as glomerulosclerosis, & many of these patients also have hypertension. An ACE inhibitor is probably the preferred initial agent in the treatment of hypertensive patients with left ventricular hypertrophy. Patients with hypertension & ischemic heart disease are candidates for treatment with ACE inhibitors; this includes treatment in the immediate post-myocardial infarction period which has been shown to lead to improved ventricular function & reduced morbidity & mortality. /ACE inhibitors/ /Salt not specified/

    Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 893

    The combination of ... quinapril and hydrochlorothiazide is indicated in the treatment of hypertension. Fixed-dosage combinations generally are not recommended for initial therapy, but are utilized in maintenance therapy after the required dose is established in order to increase convenience, economy, and patient compliance. /Included in US product labeling/ /Salt not specified/

    MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 215

    Angiotensin converting enzyme (ACE) inhibitor /Salt not specified/

    O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ: Merck and Co., Inc., 2001., p. 1441

    For more Therapeutic Uses (Complete) data for QUINAPRIL HYDROCHLORIDE (6 total), please visit the HSDB record page.

    4.3 Drug Warning

    Reduce dose ... in patients with serum creatinine > or =221 umol/L (2.5 mg/dL). /ACE Inhibitors; from table/ /Salt not specified/

    Ellenhorn, M.J., S. Schonwald, G. Ordog, J. Wasserberger. Ellenhorn's Medical Toxicology: Diagnosis and Treatment of Human Poisoning. 2nd ed. Baltimore, MD: Williams and Wilkins, 1997., p. 553

    May cause hyperkalemia in patients with renal impairment or in those receiving potassium-sparing agents. /ACE Inhibitors; from table/ /Salt not specified/

    Ellenhorn, M.J., S. Schonwald, G. Ordog, J. Wasserberger. Ellenhorn's Medical Toxicology: Diagnosis and Treatment of Human Poisoning. 2nd ed. Baltimore, MD: Williams and Wilkins, 1997., p. 553

    Can cause acute renal failure in patients with severe bilateral renal artery stenosis or severe stenosis in artery to solitary kidney. /ACE Inhibitors; from table/ /Salt not specified/

    Ellenhorn, M.J., S. Schonwald, G. Ordog, J. Wasserberger. Ellenhorn's Medical Toxicology: Diagnosis and Treatment of Human Poisoning. 2nd ed. Baltimore, MD: Williams and Wilkins, 1997., p. 553

    Conversion of quinapril to quinaprilat is reduced in patients with diminished liver function. /Salt not specified/

    Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 824

    For more Drug Warnings (Complete) data for QUINAPRIL HYDROCHLORIDE (12 total), please visit the HSDB record page.

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Angiotensin-Converting Enzyme Inhibitors

    A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)

    Antihypertensive Agents

    Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)

    Cardiovascular Agents

    Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. (See all compounds classified as Cardiovascular Agents.)

    5.2 FDA Pharmacological Classification
    5.2.1 Pharmacological Classes
    Angiotensin-converting Enzyme Inhibitors [MoA]; Angiotensin Converting Enzyme Inhibitor [EPC]
    5.3 Absorption, Distribution and Excretion

    Absorption (bioavailability) of quinapril is 60%; time to peak serum concn is 2 hr; half-life (elimination) is 2 hr; protein binding is 97%; metabolism is in the liver. /from table/ /Salt not specified/

    Ellenhorn, M.J., S. Schonwald, G. Ordog, J. Wasserberger. Ellenhorn's Medical Toxicology: Diagnosis and Treatment of Human Poisoning. 2nd ed. Baltimore, MD: Williams and Wilkins, 1997., p. 557

    Quinapril is rapidly absorbed (peak concns are achieved in 1 hr, but the peak may be delayed after food), & its rate but not extent of oral absorption (60%) may be reduced by food. Quinapril is metabolized to quinaprilat & to other minor metabolites, & quinaprilat is excreted in the urine (61%) & the feces (37%). Peak concns of quinaprilat in plasma are achieved in about 2 hr. Conversion of quinapril to quinaprilat is reduced in patients with diminished liver function. The initial half-life of quinaprilat is about 2 hr; a prolonged terminal half-life of about 25 hr may be due to high-affinity binding of the drug to tissue ACE. /Salt not specified/

    Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 823

    5.4 Metabolism/Metabolites

    Cleavage of the ester moiety by hepatic esterases transforms quinapril hydrochloride, a prodrug, into quinaprilat, an ACE inhibitor that in vitro is about as potent as benazeprilat. ... Quinapril is metabolized to quinaprilat & to other minor metabolites ... .

    Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 823

    5.5 Biological Half-Life

    The initial half-life of /the metabolite/ quinaprilat is about 2 hr; a prolonged terminal half-life of about 25 hr may be due to high-affinity binding of the drug to tissue ACE. /Salt not specified/

    Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 824

    5.6 Mechanism of Action

    Block formation of angiotensin II, promoting vasodilation & decreased aldosterone; also increased bradykinin & vasodilatory prostaglandins. /ACE Inhibitors; from table/ /Salt not specified/

    Ellenhorn, M.J., S. Schonwald, G. Ordog, J. Wasserberger. Ellenhorn's Medical Toxicology: Diagnosis and Treatment of Human Poisoning. 2nd ed. Baltimore, MD: Williams and Wilkins, 1997., p. 553

    Quinapril is deesterified to the principal metabolite, quinaprilat, which is an inhibitor of ACE activity in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor, angiotensin II. The effect of quinapril in hypertension and in congestive heart failure (CHF) appears to result primarily from the inhibition of circulating and tissue ACE activity, thereby reducing angiotensin II formation. Quinapril inhibits the elevation in blood pressure caused by iv administered angiotensin I, but has no effect on the pressor response to angiotensin II, norepinephrine or epinephrine. Angiotensin II also stimulates the secretion of aldosterone from the adrenal cortex, thereby facilitating renal sodium and fluid reabsorption. Reduced aldosterone secretion by quinapril may result in a small incr in serum potassium. In controlled hypertension trials, treatment with ACCUPRIL alone resulted in mean increases in potassium of 0.07 mmol/L ... . Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity (PRA). /Salt not specified/

    Medical Economics Co; Physicians Desk Reference 56th ed p.2611 (2002)

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"QUINAPRIL","year":"2021","qtr":"Q1","strtotime":1611685800,"product":"QUINAPRIL HYDROCHLORIDE USP (INV N. EX\/6101\/20-21 DT. 18.01.2021) (PHARMACEUTICAL RAW MATERIAL)","address":"UDYOG KSHETRA,2ND FLOOR,MULUNDGOREGAON LINK ROAD,MULUND (W),","city":"MUMBAI \/ MAHARASHTRA","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"BASLE","customer":"AIRPHARM","customerCountry":"SWITZERLAND","quantity":"6.00","actualQuantity":"6","unit":"KGS","unitRateFc":"942.5","totalValueFC":"5725.4","currency":"USD","unitRateINR":69789.168333333335,"date":"27-Jan-2021","totalValueINR":"418735.01","totalValueInUsd":"5725.4","indian_port":"BOMBAY AIR","hs_no":"29221990","bill_no":"8174187","productDescription":"API","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"UDYOG KSHETRA,2ND FLOOR,MULUNDGOREGAON LINK ROAD,MULUND (W),, MUMBAI \/ MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"QUINAPRIL HYDROCHLORIDE","year":"2021","qtr":"Q2","strtotime":1622399400,"product":"PHARMACEUTICAL RAW MATERIALS: QUINAPRIL HYDROCHLORIDE USP 41 [INV.NO. EX\/1232\/21 -22 DT. 25.05.2021]","address":"UDYOG KSHETRA,2ND FLOOR,MULUNDGOREGAON LINK ROAD,MULUND (W),","city":"MUMBAI \/ MAHARASHTRA","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"HANOI - NOIBAI","customer":"MINH DAN PHARMACEUTICAL ","customerCountry":"VIETNAM","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"888.7","totalValueFC":"8741","currency":"USD","unitRateINR":64027.5,"date":"31-May-2021","totalValueINR":"640275","totalValueInUsd":"8741","indian_port":"BOMBAY AIR","hs_no":"29221990","bill_no":"2120097","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"VIETNAM, DEMOCRATIC REP. OF","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"UDYOG KSHETRA,2ND FLOOR,MULUNDGOREGAON LINK ROAD,MULUND (W),, MUMBAI \/ MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1632508200,"product":"PHARMACEUTICAL RAW MATERIALS: QUINAPRIL","address":"UDYOG KSHETRA,2ND FLOOR,MULUNDGOREGAON LINK ROAD,MULUND (W),","city":"MUMBAI \/ MAHARASHTRA","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"BASLE","customer":"CREDIT SUISSE","customerCountry":"SWITZERLAND","quantity":"6.00","actualQuantity":"6","unit":"KGS","unitRateFc":"1000.9","totalValueFC":"5655.5","currency":"USD","unitRateINR":69333.333333333328,"date":"25-Sep-2021","totalValueINR":"416000","totalValueInUsd":"5655.5","indian_port":"BOMBAY AIR","hs_no":"29221990","bill_no":"4856458","productDescription":"API","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"UDYOG KSHETRA,2ND FLOOR,MULUNDGOREGAON LINK ROAD,MULUND (W),, MUMBAI \/ MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1714329000,"product":"PHARMACEUTICAL RAW MATERIALS: QUINAPRILHCL USP [INV.NO. PEX\/0017\/24-25 DT. 06.04.2024]","address":"2ND FLOOR, GODOWN No. 204","city":"MUMBAI","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"NEW YORK - JOHN F. K","customer":"OF..","customerCountry":"UNITED STATES","quantity":"280.86","actualQuantity":"280.86","unit":"KGS","unitRateFc":"650","totalValueFC":"173229.2","currency":"USD","unitRateINR":51505.758384960478,"date":"29-Apr-2024","totalValueINR":"14465907.3","totalValueInUsd":"173229.2","indian_port":"Bombay Air","hs_no":"29221990","bill_no":"9480651","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"2ND FLOOR, GODOWN No. 204, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1719599400,"product":"QUINAPRIL HYDROCHLORIDE PH. EUR. (PHARMACEUTICAL RAW MATERIALS) (INV NO. PEX\/0310\/24-25 DT. 26.06.2024)","address":"2ND FLOOR, GODOWN No. 204","city":"MUMBAI","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"AMSTERDAM, SCHIPHOL","customer":"TO ORDER","customerCountry":"NETHERLANDS","quantity":"159.44","actualQuantity":"159.44","unit":"KGS","unitRateFc":"765","totalValueFC":"118696.7","currency":"USD","unitRateINR":62147.084545910686,"date":"29-Jun-2024","totalValueINR":"9908731.16","totalValueInUsd":"118696.7","indian_port":"Bombay Air","hs_no":"29221990","bill_no":"2044871","productDescription":"API","marketType":"REGULATED MARKET","country":"NETHERLANDS","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"2ND FLOOR, GODOWN No. 204, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1731349800,"product":"QUINAPRIL HCL USP (PHARMACEUTICAL RAW MATERIALS) (INV NO. PEX\/0837\/24-25 DT. 28.10.2024)","address":"2ND FLOOR, GODOWN No. 204","city":"MUMBAI","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"NEW YORK - JOHN F. K","customer":"TO ORDER","customerCountry":"UNITED STATES","quantity":"227.94","actualQuantity":"227.94","unit":"KGS","unitRateFc":"650","totalValueFC":"143600","currency":"USD","unitRateINR":53163.759980696668,"date":"12-Nov-2024","totalValueINR":"12118147.45","totalValueInUsd":"143600","indian_port":"Bombay Air","hs_no":"29221990","bill_no":"5539441","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"2ND FLOOR, GODOWN No. 204, MUMBAI","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1642185000,"product":"QUINAPRIL HYDROCHLORIDE","address":"11TH FLR.GRANDEUR,OPP.GUNDECHA,SYM PHONY, VEERA DESAI RD.EXTENSION","city":"MUMBAI SUBURBAN,MAHARASHTRA","supplier":"TEVA PHARMACEUTICAL INDUSTRIES","supplierCountry":"SPAIN","foreign_port":"#N\/A","customer":"MARKSANS PHARMA","customerCountry":"INDIA","quantity":"235.67","actualQuantity":"235.67","unit":"KGS","unitRateFc":"600","totalValueFC":"162958.8","currency":"EUR","unitRateINR":"51510","date":"15-Jan-2022","totalValueINR":"12139361.7","totalValueInUsd":"162958.8","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"7094255","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"#N\/A","supplierAddress":"","customerAddress":"11TH FLR.GRANDEUR,OPP.GUNDECHA,SYM PHONY, VEERA DESAI RD.EXTENSION"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1646850600,"product":"QUINAPRIL HYDROCHLORIDE","address":"11TH FLR.GRANDEUR,OPP.GUNDECHA,SYM PHONY, VEERA DESAI RD.EXTENSION","city":"MUMBAI SUBURBAN,MAHARASHTRA","supplier":"TEVA PHARMACEUTICAL INDUSTRIES","supplierCountry":"SPAIN","foreign_port":"NA","customer":"MARKSANS PHARMA","customerCountry":"INDIA","quantity":"226.83","actualQuantity":"226.83","unit":"KGS","unitRateFc":"600","totalValueFC":"153026.4","currency":"EUR","unitRateINR":"51420","date":"10-Mar-2022","totalValueINR":"11663598.6","totalValueInUsd":"153026.4","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"7812936","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"11TH FLR.GRANDEUR,OPP.GUNDECHA,SYM PHONY, VEERA DESAI RD.EXTENSION"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1658169000,"product":"QUINAPRIL HYDROCHLORIDE 158-20-0005","address":"11TH FLR.GRANDEUR,OPP.GUNDECHA,SYM PHONY, VEERA DESAI RD.EXTENSION","city":"MUMBAI SUBURBAN,MAHARASHTRA","supplier":"TEVA PHARMACEUTICAL INDUSTRIES","supplierCountry":"SPAIN","foreign_port":"NA","customer":"MARKSANS PHARMA","customerCountry":"INDIA","quantity":"252.81","actualQuantity":"252.81","unit":"KGS","unitRateFc":"750","totalValueFC":"195887","currency":"EUR","unitRateINR":"61612.5","date":"19-Jul-2022","totalValueINR":"15576256.13","totalValueInUsd":"195887","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"9613684","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"11TH FLR.GRANDEUR,OPP.GUNDECHA,SYM PHONY, VEERA DESAI RD.EXTENSION"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1673289000,"product":"QUINAPRIL HYDROCHLORIDE","address":"11TH FLR.GRANDEUR,OPP.GUNDECHA,SYM PHONY, VEERA DESAI RD.EXTENSION","city":"MUMBAI SUBURBAN,MAHARASHTRA","supplier":"ZHEJIANG HUAHAI PHARMACEUTICAL","supplierCountry":"CHINA","foreign_port":"NA","customer":"MARKSANS PHARMA","customerCountry":"INDIA","quantity":"15.00","actualQuantity":"15","unit":"KGS","unitRateFc":"650","totalValueFC":"11179.2","currency":"USD","unitRateINR":"60933.6","date":"10-Jan-2023","totalValueINR":"914004","totalValueInUsd":"11179.2","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"4119506","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"11TH FLR.GRANDEUR,OPP.GUNDECHA,SYM PHONY, VEERA DESAI RD.EXTENSION"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677868200,"product":"QUINAPRIL HYDROCHLORIDE (QTY:2 X 400 MG, PRICE USD:552\/EACH)(FOC)","address":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,","city":"TURKAPALLY-V SHAMIRPET HYDERABAD,TE","supplier":"USP","supplierCountry":"INDIA","foreign_port":"NA","customer":"UNITED STATES PHARMACOPEIA ","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.0008","unit":"KGS","unitRateFc":"1380000","totalValueFC":"1170.4","currency":"USD","unitRateINR":"120332150","date":"04-Mar-2023","totalValueINR":"96265.72","totalValueInUsd":"1170.4","indian_port":"HYDERABAD AIR","hs_no":"29334900","bill_no":"4910660","productDescription":"Re-Import","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,"}]
    27-Jan-2021
    12-Nov-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - TABLET;ORAL - EQ 10MG BASE **Federal...DOSAGE - TABLET;ORAL - EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 19885

    read-more

    DOSAGE - TABLET;ORAL - EQ 20MG BASE **Federal...DOSAGE - TABLET;ORAL - EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 19885

    read-more

    DOSAGE - TABLET;ORAL - EQ 40MG BASE **Federal...DOSAGE - TABLET;ORAL - EQ 40MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 19885

    read-more

    DOSAGE - TABLET;ORAL - EQ 5MG BASE **Federal ...DOSAGE - TABLET;ORAL - EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 19885

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Granulation

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Topical

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Parenteral

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    USP

    read-more
    read-more

    ABOUT THIS PAGE

    Quinapril hydrochloride Manufacturers

    A Quinapril hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Quinapril hydrochloride, including repackagers and relabelers. The FDA regulates Quinapril hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Quinapril hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Quinapril hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Quinapril hydrochloride Suppliers

    A Quinapril hydrochloride supplier is an individual or a company that provides Quinapril hydrochloride active pharmaceutical ingredient (API) or Quinapril hydrochloride finished formulations upon request. The Quinapril hydrochloride suppliers may include Quinapril hydrochloride API manufacturers, exporters, distributors and traders.

    click here to find a list of Quinapril hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Quinapril hydrochloride USDMF

    A Quinapril hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Quinapril hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Quinapril hydrochloride DMFs exist exist since differing nations have different regulations, such as Quinapril hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Quinapril hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Quinapril hydrochloride USDMF includes data on Quinapril hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Quinapril hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Quinapril hydrochloride suppliers with USDMF on PharmaCompass.

    Quinapril hydrochloride CEP

    A Quinapril hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Quinapril hydrochloride Certificate of Suitability (COS). The purpose of a Quinapril hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Quinapril hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Quinapril hydrochloride to their clients by showing that a Quinapril hydrochloride CEP has been issued for it. The manufacturer submits a Quinapril hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Quinapril hydrochloride CEP holder for the record. Additionally, the data presented in the Quinapril hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Quinapril hydrochloride DMF.

    A Quinapril hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Quinapril hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

    click here to find a list of Quinapril hydrochloride suppliers with CEP (COS) on PharmaCompass.

    Quinapril hydrochloride WC

    A Quinapril hydrochloride written confirmation (Quinapril hydrochloride WC) is an official document issued by a regulatory agency to a Quinapril hydrochloride manufacturer, verifying that the manufacturing facility of a Quinapril hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Quinapril hydrochloride APIs or Quinapril hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Quinapril hydrochloride WC (written confirmation) as part of the regulatory process.

    click here to find a list of Quinapril hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.

    Quinapril hydrochloride NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Quinapril hydrochloride as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Quinapril hydrochloride API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Quinapril hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Quinapril hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Quinapril hydrochloride NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Quinapril hydrochloride suppliers with NDC on PharmaCompass.

    Quinapril hydrochloride GMP

    Quinapril hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Quinapril hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Quinapril hydrochloride GMP manufacturer or Quinapril hydrochloride GMP API supplier for your needs.

    Quinapril hydrochloride CoA

    A Quinapril hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Quinapril hydrochloride's compliance with Quinapril hydrochloride specifications and serves as a tool for batch-level quality control.

    Quinapril hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Quinapril hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Quinapril hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Quinapril hydrochloride EP), Quinapril hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Quinapril hydrochloride USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search